Michael Duran
Interventional Cardiology · Bedford, TXNPI 1700888229
Payments from drug & device makers
Across 109 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novartis$225
- Astellas Pharma US Inc$223
- Sanofi-aventis U.S. LLC$170
- Smith+Nephew$150
- Boston Scientific$148
- plus $956 from 20 others
What the payments were for
- Consulting fees$71424%
- Food & beverage$2,12871%
- Education$1575%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $1,128 |
| Novartis | 15 | $225 |
| Astellas Pharma US Inc | 5 | $223 |
| Sanofi-aventis U.S. LLC | 11 | $170 |
| Smith+Nephew | 1 | $150 |
| Boston Scientific | 3 | $148 |
| Johnson & Johnson | 7 | $119 |
| Abiomed | 1 | $118 |
| Pfizer | 7 | $115 |
| Merck | 6 | $99 |
| Amarin Pharma, Inc. | 4 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $39 |
| Cardiovascular Systems Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Medtronic | 1 | $20 |
| Gilead | 1 | $17 |
| Angiodynamics, Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Amgen | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Allure Quadra RF CRT Pacemaker$714
- REDAPT$150
- Impella$118
How this compares
$2,999 in reported general payments places this provider in the 15th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $24,297 |
| XareltoRivaroxaban | 14 | $15,748 |
| Metoprolol Succinate | 39 | $556 |
| ClopidogrelClopidogrel Bisulfate | 14 | $233 |
| Losartan Potassium | 22 | $186 |
| Atorvastatin Calcium | 12 | $162 |
| Amlodipine Besylate | 19 | $143 |
| Lisinopril | 12 | $100 |
| Nitroglycerin | 11 | $81 |
| Furosemide | 13 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $24,29732 claims |
| Johnson & JohnsonXarelto | $119 | $15,74814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Bedford
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.